CA-C3.AI/NCS
17.6.2021 06:02:07 CEST | Business Wire | Press release
C3 AI (NYSE:AI), the Enterprise AI application software company, and NCS, a leading technology services provider and member of the Singtel Group, today announced a strategic partnership focused on delivering enterprise AI solutions to clients in Southeast Asia (SEA) and Australia/New Zealand (ANZ) across multiple industries, including telecommunications, government, financial services, transportation, and more.
This agreement represents C3 AI’s first strategic partnership with a telecommunications group. NCS will leverage its deep domain experience and technology expertise in serving governments and businesses in SEA and ANZ, investing up to S$10 million to develop and deploy enterprise AI applications created on the C3 AI® Suite. C3 AI’s solutions will also be deployed across Singtel, Optus, and other affiliated telecommunications networks to bring the advantages of enterprise AI to their operations and clients.
As the leader in enterprise AI applications, C3 AI’s offerings include the C3 AI Suite, a powerful end-to-end enterprise AI platform; C3 AI Ex Machina, a no-code solution that anyone can use to generate actionable enterprise AI insights; C3 AI CRM, the first enterprise AI-powered CRM solution custom-built for industries; and a comprehensive inventory of pre-built enterprise AI applications. These applications cover a broad range of use cases, such as C3 AI Energy Management for optimizing energy consumption and carbon emissions, C3 AI Predictive Maintenance to reduce unplanned machine downtime, and C3 AI Fraud Detection for financial transactions.
“Our partnership with C3 AI reaffirms NCS’ commitment to build a strong digital partner ecosystem that provides our clients access to world-leading technologies and enterprise solutions,” said NCS CEO Ng Kuo Pin. “We believe that the wave of enterprise-grade AI solutions has arrived and are excited to work with our clients to build the next generation of digital applications with enterprise AI embedded. We look forward to playing our part to unleash the transformative power of enterprise AI across governments and enterprises in Asia-Pacific.”
In its 2021 Global CIO Agenda survey, Gartner found that SEA and ANZ were among the fastest-growing regions in the world to apply digitalization to optimize enterprise processes1 . In addition, CIOs in these regions identified Artificial Intelligence/Machine Learning as a game-changing technology2 . To capitalize on this trend, C3 AI and NCS will establish a Center of Excellence together to jointly explore new solutions that will accelerate the adoption of enterprise AI and develop custom-built offerings tailored to the business requirements of the Asia-Pacific market.
“Our Center of Excellence will bring together experts from C3 AI and NCS to carefully study and respond to the specific needs of organizations and industries in Southeast Asia, Australia, and New Zealand,” said General Manager, Industries and Alliances at C3 AI Gene Reznik. “This will allow us to better serve customers in SEA and ANZ and provide them with the enterprise AI solutions they require to achieve their digital transformation objectives.”
“Singtel and NCS are clear leaders in the deployment and implementation of telecommunication and cloud solutions, and we are incredibly excited to be joining forces with such a respected and forward-looking partner,” said C3 AI Chairman and CEO Thomas M. Siebel. “NCS’ focus on digital transformation will help drive enterprise AI in Asia-Pacific, especially in the telecommunications industry, on a massive scale.”
1 Gartner, '2021 CIO Agenda: Global Perspectives on 'Seize This Opportunity for Digital Business Acceleration', Andy Rowsell-Jones, Tomas Neilsen, Jan-Martin Lowendahl, Chris Howard, Monika Sinha, March 05, 2021
2 Gartner, '2021 CIO Agenda: A Southeast Asia Perspective', Adrian Lee, February 03, 2021; Gartner, '2021 CIO Agenda: An Australia and New Zealand Perspective', Andy Rowsell-Jones, Brian Ferreira, Christopher Bell, December 15, 2021
About C3.ai, Inc.
C3.ai, Inc. (NYSE:AI) is the Enterprise AI application software company that accelerates digital transformation for organizations globally. C3 AI delivers a family of fully integrated products: C3 AI® Suite, an end-to-end platform for developing, deploying, and operating large-scale AI applications; C3 AI Applications, a portfolio of industry-specific SaaS AI applications; C3 AI CRM, a suite of industry-specific CRM applications designed for AI and machine learning; and C3 AI Ex Machina, a no-code AI solution to apply data science to everyday business problems. The core of the C3 AI offering is an open, model-driven AI architecture that dramatically simplifies data science and application development. Learn more at: www.c3.ai
About NCS
NCS is a member of the Singtel Group and the leading information, communications and technology (ICT) service provider with presence in the Asia Pacific region. NCS delivers end-to-end ICT and digital solutions to help governments and enterprises realise business value through digital transformation and the innovative use of technology. NCS invests in NEXT capabilities of digital, cloud, platform and cyber while continuously strengthening its core offerings of Applications, Infrastructure and Engineering. NCS also believes in building a strong partner eco-system with leading technology players and research institutions to support open innovation and co-creation.
For more information, please visit www.ncs.com.sg .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210616006026/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom